2. Bonfrer JM, Gaarenstroom KN, Korse CM, Van Bunningen BN, Kenemans P. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Anticancer Res 1997;17:2329-2334. PMID:
9245246.
3. Esajas MD, Duk JM, de Bruijn HW, Aalders JG, Willemse PH, Sluiter W, et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol 2001;19:3960-3966. PMID:
11579117.
4. Avall-Lundqvist EH, Sjovall K, Nilsson BR, Eneroth PH. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma. Eur J Cancer 1992;28A:1695-1702. PMID:
1389488.
5. Duk JM, Groenier KH, de Bruijn HW, Hollema H, ten Hoor KA, van der Zee AG, et al. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 1996;14:111-118. PMID:
8558185.
6. Yuan CC, Wang PH, Ng HT, Tsai LC, Juang CM, Chiu LM. Both TPA and SCC-Ag levels are prognostic even in highrisk stage Ib-IIa cervical carcinoma as determined by a stratification analysis. Eur J Gynaecol Oncol 2002;23:17-20. PMID:
11876385.
7. Strauss HG, Laban C, Lautenschlager C, Buchmann J, Schneider I, Koelbl H. SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix. Eur J Cancer 2002;38:1987-1991. PMID:
12376202.
8. Molina R, Filella X, Lejarcegui JA, Pahisa J, Torne A, Rovirosa A, et al. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumour Biol 2003;24:156-164. PMID:
14610320.
9. Reesink-Peters N, van der Velden J, Ten Hoor KA, Boezen HM, de Vries EG, Schilthuis MS, et al. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J Clin Oncol 2005;23:1455-1462. PMID:
15735121.
10. Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Van de Vijver MJ, Fleuren GJ, et al. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis. Gynecol Oncol 2000;77:164-170. PMID:
10739706.
11. Scambia G, Panici PB, Baiocchi G, Amoroso M, Foti E, Greggi S, et al. The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy. Am J Obstet Gynecol 1991;164:631-636. PMID:
1992715.
12. Micke O, Prott FJ, Schafer U, Tangerding S, Potter R, Willich N. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res 2000;20:5113-5115. PMID:
11326679.
13. Ohara K, Tanaka Y, Tsunoda H, Nishida M, Sugahara S, Itai Y. Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging. Obstet Gynecol 2002;100:781-787. PMID:
12383549.
14. Maiman M. The clinical application of serum squamous cell carcinoma antigen level monitoring in invasive cervical carcinoma. Gynecol Oncol 2002;84:4-6. PMID:
11748968.
15. Gadducci A, Tana R, Fanucchi A, Genazzani AR. Biochemical prognostic factors and risk of relapses in patients with cervical cancer. Gynecol Oncol 2007;107(1 Suppl 1):S23-S26. PMID:
17727924.
16. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol 2008;66:10-20. PMID:
17964182.
17. Abe A, Nakano T, Morita S, Oka K. Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer. Anticancer Res 1999;19:829-836. PMID:
10216501.
18. Bolger BS, Dabbas M, Lopes A, Monaghan JM. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol Oncol 1997;65:309-313. PMID:
9159343.
19. Hong JH, Tsai CS, Chang JT, Wang CC, Lai CH, Lee SP, et al. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys 19981;41:823-830. PMID:
9652844.
20. Dorfman RE, Alpern MB, Gross BH, Sandler MA. Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology 1991;180:319-322. PMID:
2068292.
21. Nicolet V, Carignan L, Bourdon F, Prosmanne O. MR imaging of cervical carcinoma: a practical staging approach. Radiographics 2000;20:1539-1549. PMID:
11112809.
22. Miller C, Elkas JC. Cervical and vaginal cancer. In: Berek JS, editors. Berek & Novak's gynecology. 15th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2012. p. 1304-1349.
23. Montag TW. Tumor markers in gynecologic oncology. Obstet Gynecol Surv 1990;45:94-105. PMID:
2405313.
24. Duk JM, de Bruijn HW, Groenier KH, Hollema H, ten Hoor KA, Krans M, et al. Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations. Gynecol Oncol 1990;39:186-194. PMID:
2227594.
25. de Bruijn HW, Duk JM, van der Zee AG, Pras E, Willemse PH, Boonstra H, et al. The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix. Tumour Biol 1998;19:505-516. PMID:
9817980.
26. Davelaar EM, van de Lande J, von Mensdorff-Pouilly S, Blankenstein MA, Verheijen RH, Kenemans P. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer. Tumour Biol 2008;29:9-17. PMID:
18497544.
27. Gadducci A, Scambia G, Panici PB, Ferdeghini M, Battaglia F, Caenaro G, et al. The prognostic relevance of pretreatment serum immunosuppressive acidic protein (IAP) in patients with squamous cell carcinoma of the uterine cervix: a comparison with squamous cell carcinoma antigen (SCC). Cancer J 1994;7:241-247.
28. Boss EA, Barentsz JO, Massuger LF, Boonstra H. The role of MR imaging in invasive cervical carcinoma. Eur Radiol 2000;10:256-270. PMID:
10663755.
29. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527. PMID:
12571259.
30. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006;208:152-164. PMID:
16362994.
31. de Cremoux P, de la Rochefordiere A, Savignoni A, Kirova Y, Alran S, Fourchotte V, et al. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype. Int J Cancer 2009;124:778-782. PMID:
19035459.
32. Lai CH, Chang CJ, Huang HJ, Hsueh S, Chao A, Yang JE, et al. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery. J Clin Oncol 2007;25:3628-3634. PMID:
17704412.
33. Schwartz SM, Daling JR, Shera KA, Madeleine MM, McKnight B, Galloway DA, et al. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol 2001;19:1906-1915. PMID:
11283122.